Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI)

BMC Pediatrics

Study Protocol

Giovanni Cioni¹  Francesca Tinelli¹  Giancarlo la Marca²  Claudio Fonda³  Sara Savelli³  Gianpaolo Donzelli⁴  Alberto Spalice⁵  Rosa Scaramuzzo⁶  Maria Luisa Della Bona⁷  Sabrina Malvagia⁷  Marta Daniotti⁸  Luca Filippi⁸  Patrizio Fiorini⁸  Serena Catarzi⁸  Laura Bartalena⁹  Matteo Giampietri⁹  Antonio Boldrini⁹  Tiziana Pisano^1,10  Melania Falchi^1,10  Renzo Guerrini^1,10  Francesca Del Balzo^1,11  Paola Papoff^1,11 

[1] Department of Developmental Neuroscience, Stella Maris Scientific Institute, Viale del Tirreno, 331, Calambrone, I-56128, Pisa, Italy;Department of Pharmacology, University of Florence, Viale Pieraccini, 6, I-50139, Florence, Italy;Laboratory for diseases of the nervous system and metabolism, “A. Meyer” University Children’s Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy;Department of Radiological Sciences, “A. Meyer” University Children's Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy;Department of Sciences for Woman and Child's Health, University of Florence, “A. Meyer” Children's Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy;Division of Child Neurology, Department of Pediatrics, La Sapienza University of Rome, Viale del Policlinico, 155, I-00186, Rome, Italy;Istituto di Scienze della Vita, Scuola Superiore Sant’Anna, Piazza Martiri della Libertà, 33, I-56127, Pisa, Italy;Laboratory for diseases of the nervous system and metabolism, “A. Meyer” University Children’s Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy;Neonatal Intensive Care Unit, Medical Surgical Feto-Neonatal Department, “A. Meyer” University Children’s Hospital, Viale Pieraccini, 24, I-50139, Florence, Italy;Neonatal Unit, University of Pisa, Via Roma, 67, I-56126, Pisa, Italy;Paediatric Neurology Unit and Laboratories, “A. Meyer” Children’s Hospital, University of Florence, Viale Pieraccini, 24, I-50139, Florence, Italy;Pediatric Emergency and Intensive Care, Department of Pediatrics, La Sapienza University of Rome, Viale del Policlinico, 155, I-00186, Rome, Italy;

关键词: Neonatal hypoxic-ischemic encephalopathy;    Therapeutic hypothermia;    Topiramate;   

DOI  :  10.1186/1471-2431-12-144

 received in 2012-08-22, accepted in 2012-08-31,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundDespite progresses in neonatal care, the mortality and the incidence of neuro-motor disability after perinatal asphyxia have failed to show substantial improvements. In countries with a high level of perinatal care, the incidence of asphyxia responsible for moderate or severe encephalopathy is still 2–3 per 1000 term newborns. Recent trials have demonstrated that moderate hypothermia, started within 6 hours after birth and protracted for 72 hours, can significantly improve survival and reduce neurologic impairment in neonates with hypoxic-ischemic encephalopathy. It is not currently known whether neuroprotective drugs can further improve the beneficial effects of hypothermia. Topiramate has been proven to reduce brain injury in animal models of neonatal hypoxic ischemic encephalopathy. However, the association of mild hypothermia and topiramate treatment has never been studied in human newborns. The objective of this research project is to evaluate, through a multicenter randomized controlled trial, whether the efficacy of moderate hypothermia can be increased by concomitant topiramate treatment.Methods/DesignTerm newborns (gestational age ≥ 36 weeks and birth weight ≥ 1800 g) with precocious metabolic, clinical and electroencephalographic (EEG) signs of hypoxic-ischemic encephalopathy will be randomized, according to their EEG pattern, to receive topiramate added to standard treatment with moderate hypothermia or standard treatment alone. Topiramate will be administered at 10 mg/kg once a day for the first 3 days of life. Topiramate concentrations will be measured on serial dried blood spots. 64 participants will be recruited in the study. To evaluate the safety of topiramate administration, cardiac and respiratory parameters will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance. To evaluate the efficacy of topiramate, the neurologic outcome of enrolled newborns will be evaluated by serial neurologic and neuroradiologic examinations. Visual function will be evaluated by means of behavioural standardized tests.DiscussionThis pilot study will explore the possible therapeutic role of topiramate in combination with moderate hypothermia. Any favourable results of this research might open new perspectives about the reduction of cerebral damage in asphyxiated newborns.Trial registrationCurrent Controlled Trials ISRCTN62175998; ClinicalTrials.gov Identifier NCT01241019; EudraCT Number 2010-018627-25

【 授权许可】

CC BY   
© Filippi et al.; licensee BioMed Central Ltd. 2012